In this phase 1/1b trial (NCT06040541), the ORR was 30%, and the DCR was 80%, with no reported dose-limiting toxicities, and the maximum tolerated dose was not reached.320 RMC-8839 is a first-in-class KRAS-on inhibitor that targets KRASG13C in its GTP-bound state, highlighting again the increased dependence of KRASG13C-mutant cancers on wild-type RAS isoforms.321 Both of these compounds were recently presented and discussed at the EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics in October 2024. This evidence concerns the gene KRAS and cancer.